Novel nanoparticle vaccines for Listeriosis.

Abstract:

:In recent years, nanomedicine has transformed many areas of traditional medicine, and enabled fresh insights into the prevention of previously difficult to treat diseases. An example of the transformative power of nanomedicine is a recent nano-vaccine against listeriosis, a serious bacterial infection affecting not only pregnant women and their neonates, but also immune-compromised patients with neoplastic or chronic autoimmune diseases. There is a major unmet need for an effective and safe vaccine against listeriosis, with the challenge that an effective vaccine needs to generate protective T cell immunity, a hitherto difficult to achieve objective. Now utilizing a gold nanoparticle antigen delivery approach together with a novel polysaccharide nanoparticulate adjuvant, an effective T-cell vaccine has been developed that provides robust protection in animal models of listeriosis, raising the hope that one day this nanovaccine technology may protect immune-compromised humans against this serious opportunistic infection.

journal_name

Hum Vaccin Immunother

authors

Calderon-Gonzalez R,Marradi M,Garcia I,Petrovsky N,Alvarez-Dominguez C

doi

10.1080/21645515.2015.1063756

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

2501-3

issue

10

eissn

2164-5515

issn

2164-554X

journal_volume

11

pub_type

杂志文章
  • Viral etiological causes of febrile seizures for respiratory pathogens (EFES Study).

    abstract:BACKGROUND:Febrile seizure is the most common childhood neurological disorder, is an important health problem with potential short- and long-term complications, also leading to economic burden and increased parental anxiety about fevers and seizures occurring in their children. There are no routine recommendation to de...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1080/21645515.2018.1526588

    authors: Carman KB,Calik M,Karal Y,Isikay S,Kocak O,Ozcelik A,Yazar AS,Nuhoglu C,Sag C,Kilic O,Dinleyici M,Lacinel Gurlevik S,Yimenicioglu S,Ekici A,Perk P,Tosun A,Isik I,Yarar C,Arslantas D,Dinleyici EC

    更新日期:2019-01-01 00:00:00

  • Acute respiratory failure due to eosinophilic pneumonia following pneumococcal vaccination.

    abstract::A 68-year-old woman under maintenance hemodialysis was admitted to our hospital with fever and dyspnea that had developed two days after the second vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV23). She had received the first vaccination with PPV23 five years earlier without any complications....

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1631134

    authors: Kikuchi R,Iwai Y,Watanabe Y,Nakamura H,Aoshiba K

    更新日期:2019-01-01 00:00:00

  • Synthesis and immunogenicity evaluation of Salmonella enterica serovar Paratyphi A O-specific polysaccharide conjugated to diphtheria toxoid.

    abstract::Salmonella enterica serovar Paratyphi A (S. Paratyphi A) is a human restricted pathogen that can cause systemic infection (paratyphoid fever) with recently increased incidence particularly in developing countries. Currently there is no licensed vaccine for prevention of infection from S. Paratyphi A. In this study the...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.28130

    authors: Ali A,An SJ,Cui C,Haque A,Carbis R

    更新日期:2014-01-01 00:00:00

  • Field seasonal influenza vaccine effectiveness: evaluation of the screening method using different sources of data during the 2010/2011 French influenza season.

    abstract::Thanks to the screening method, we estimated among target groups the 2010/2011 field vaccine effectiveness (FVE) against laboratory confirmed influenza cases seen in general practice. We also compared the values of FVE estimations obtained by using three sources of the population vaccination coverage (VC) based on thr...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.25513

    authors: Falchi A,Souty C,Grisoni ML,Mosnier A,Hanslik T,Daviaud I,Varesi L,Kerneis S,Carrat F,Blanchon T

    更新日期:2013-11-01 00:00:00

  • Regional variations in HPV vaccination among 9-17 year old adolescent females from the BRFSS, 2008-2010.

    abstract::Human papillomavirus (HPV) vaccine uptake among 18-26 y old women varies by geographic region in the US. However, little is known about regional variations in vaccination among girls who are in the vaccine's targeted age groups. Regional variation in HPV vaccination among female adolescents (9-17 y old) was examined u...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/21645515.2014.980202

    authors: Hirth JM,Rahman M,Smith JS,Berenson AB

    更新日期:2014-01-01 00:00:00

  • The development of a recombinant hepatitis E vaccine HEV 239.

    abstract::Hepatitis E virus (HEV) infection is one of the main causes of acute hepatitis worldwide. A recombinant hepatitis E vaccine, HEV 239, has been licensed in China for immunizing adults of 16 y old and above. The vaccine antigen contains pORF2 aa 368 - 606 of the HEV genotype 1 expressed in E. coli. The quality of the va...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2015.1008870

    authors: Li SW,Zhao Q,Wu T,Chen S,Zhang J,Xia NS

    更新日期:2015-01-01 00:00:00

  • Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence.

    abstract::Immunocompromising conditions increase the risk of invasive pneumococcal disease (IPD). Vaccine uptake in patients with these conditions may be low in part because of concerns about decreased immunogenicity and safety in these high-risk groups. We conducted a literature search to identify publications describing antib...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1735224

    authors: Chilson E,Scott DA,Schmoele-Thoma B,Watson W,Moran MM,Isturiz R

    更新日期:2020-11-01 00:00:00

  • Morbidity and mortality of vulvar and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccines.

    abstract::Vaginal and vulvar cancers do not account for a large proportion of gynecologic malignancies but their impact is significant. Both vaginal and vulvar lesions have precursors and display levels of dysplasia before progression to invasive disease. Human Papillomavirus (HPV) is a known causative agent of such dysplasia a...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2016.1147634

    authors: Buchanan TR,Graybill WS,Pierce JY

    更新日期:2016-06-02 00:00:00

  • Two cases of disseminated BCG disease following vaccination in the same family: case reports and review of the literature in China.

    abstract::Disseminated bacillus Calmette-Guérin (BCG) disease is a rare and serious adverse event following immunization (AEFI) with BCG. Here, we reported two cases of disseminated BCG disease in the same family and reviewed the literature to identify another 35 cases in China. The average age at onset was 3.7 ± 2.1 months amo...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1819102

    authors: Wang J,Wu QS,Jiang MB,Xu ZH

    更新日期:2020-10-20 00:00:00

  • Improvement of influenza vaccine strain A/Vietnam/1194/2004 (H5N1) growth with the neuraminidase packaging sequence from A/Puerto Rico/8/34.

    abstract::H5N1 influenza candidate vaccine viruses were developed using the "6+2" approach. The hemagglutinin (HA) and neuraminidase (NA) genes were derived from the popular H5N1 virus and the remaining six internal segments were derived from the A/Puerto Rico/8/34 strain (H1N1, PR8). However, some of these candidate strains ha...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.18468

    authors: Pan W,Dong Z,Meng W,Zhang W,Li T,Li C,Zhang B,Chen L

    更新日期:2012-02-01 00:00:00

  • Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination.

    abstract::Attenuated measles virus (MV) is one of the most effective and safe vaccines available, making it attractive candidate vector to prevent infectious diseases. Attenuated MV have acquired the ability to use the complement regulator CD46 as a major receptor to mediate virus entry and intercellular fusion. Therefore, atte...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2015.1122146

    authors: Baldo A,Galanis E,Tangy F,Herman P

    更新日期:2016-05-03 00:00:00

  • A new therapeutic potential for cancers: One CAR with 2 different engines!

    abstract::Tumor cells escape from immune recognition by several mechanisms such as down-regulating of MHC class I molecules, losing of tumor antigens, etc. The purpose of cancer immunotherapy is to robust or reconstruct the capacity of the immune system to recognize and kill tumor cells by overwhelming the mechanisms by which t...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 信件

    doi:10.1080/21645515.2017.1314874

    authors: Sheikhi A,Jafarzadeh A

    更新日期:2017-08-03 00:00:00

  • Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugated vaccine (PHiD-CV) co-administered with DTPa-combined vaccines

    abstract::Prophylactic paracetamol administration impacts vaccine immune response; this study ( www.clinicaltrials.gov : NCT01235949) is the first to assess PHiD-CV immunogenicity following prophylactic ibuprofen administration. In this phase IV, multicenter, open-label, randomized, controlled, non-inferiority study in Romania ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1080/21645515.2016.1223001

    authors: Falup-Pecurariu O,Man SC,Neamtu ML,Chicin G,Baciu G,Pitic C,Cara AC,Neculau AE,Burlea M,Brinza IL,Schnell CN,Sas V,Lupu VV,François N,Swinnen K,Borys D

    更新日期:2017-03-04 00:00:00

  • Report from the field: Fifth Vaccine Renaissance in Providence RI.

    abstract::When the next pandemic emerges, will we be ready? Experts say that the number of animal to human "species jumps" is bound to increase as populations increase and the speed of travel between continents accelerates. Typical pandemic timelines no longer apply.(1) Pandemic H1N1 traveled the world in just weeks, as did SAR...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.19779

    authors: Spero D,Petrovsky N,De Groot AS

    更新日期:2012-07-01 00:00:00

  • HPV vaccine hesitancy among parents in Italy: a cross-sectional study.

    abstract::This cross-sectional survey determined the vaccine hesitancy related to Human papillomavirus (HPV) and the determinants among parents of adolescents aged 12 and 13 years in Italy. Data was collected through a self-administered questionnaire. Two-thirds of the parents (66.7%) had heard of HPV infection and knew that th...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1744367

    authors: Della Polla G,Pelullo CP,Napolitano F,Angelillo IF

    更新日期:2020-11-01 00:00:00

  • Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination.

    abstract::Varicella zoster virus (VZV) is primarily known for causing varicella in childhood, but can reactivate again as herpes zoster (HZ) after a period of latency, mainly in persons older than 50 years. Universal varicella vaccination was introduced in Germany in 2004, while HZ vaccination has not been recommended yet. We a...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2015.1135279

    authors: Horn J,Karch A,Damm O,Kretzschmar ME,Siedler A,Ultsch B,Weidemann F,Wichmann O,Hengel H,Greiner W,Mikolajczyk RT

    更新日期:2016-07-02 00:00:00

  • In vitro characterization and preclinical immunogenicity of Typhax, a typhoid fever protein capsular matrix vaccine candidate.

    abstract::Typhax is an investigational typhoid fever vaccine candidate that was GMP manufactured applying Protein Capsular Matrix Vaccine (PCMV) technology. It consists of Vi polysaccharide antigen, derived from S. Typhi, non-covalently entrapped in a glutaraldehyde catalyzed cross-linked α-poly-L-lysine and CRM197 protein matr...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1599674

    authors: Griffin TJ 4th,Thanawastien A,Cartee RT,Mekalanos JJ,Killeen KP

    更新日期:2019-01-01 00:00:00

  • Influenza vaccine effectiveness among healthcare workers in comparison to hospitalized patients: A 2004-2009 case-test, negative-control, prospective study.

    abstract::The objective of this study was to calculate Vaccine Effectiveness (VE) in healthcare workers (HCW) and to compare VE between patients and HCW. A case-control investigation based on the prospective study was conducted between 2004 and 2009 in a teaching hospital. All HCW with influenza-like illness (ILI) from particip...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2015.1079677

    authors: Vanhems P,Baghdadi Y,Roche S,Bénet T,Regis C,Lina B,Robert O,Voirin N,Ecochard R,Amour S

    更新日期:2016-01-01 00:00:00

  • Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types.

    abstract::In the clinical trials of the quadrivalent human papillomavirus (qHPV) vaccine, antibodies were measured by a competitive Luminex immunoassay (HPV-4 cLIA). A nine-valent HPV (9vHPV) vaccine targeting the types in the qHPV vaccine (HPV6/11/16/18), as well as 5 of the next most frequent HPV types found in cervical cance...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/hv.29205

    authors: Roberts C,Green T,Hess E,Matys K,Brown MJ,Haupt RM,Luxembourg A,Vuocolo S,Saah A,Antonello J

    更新日期:2014-01-01 00:00:00

  • Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: an a posteriori evaluation and forecast of future benefits.

    abstract::Italy was one of the first countries in the world to introduce a routine vaccination program against HBV for newborns and 12-y-old children. From a clinical point of view, such strategy was clearly successful. The objective of our study was to verify whether, at 20 y from its implementation, hepatitis B universal vacc...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.23827

    authors: Boccalini S,Taddei C,Ceccherini V,Bechini A,Levi M,Bartolozzi D,Bonanni P

    更新日期:2013-05-01 00:00:00

  • Zika vaccine pre-clinical and clinical data review with perspectives on the future development.

    abstract::Zika is an arboviral illness caused by infection with the Zika flavivirus. Transmission most commonly occurs during a feeding event involving an infected Aedes mosquito or vertical transmission between an infected mother to her fetus. Infection outcomes range from asymptomatic to devastating neurologic injuries in chi...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1730657

    authors: Thomas SJ,Barrett A

    更新日期:2020-10-02 00:00:00

  • Impact of SA 14-14-2 vaccination on the occurrence of Japanese encephalitis in India.

    abstract::Japanese encephalitis virus is the major cause of encephalitis in India. To control the increasing incidence and fatal outbreaks, SA 14-14-2 vaccine was introduced initially in 104 endemic districts in phased manner from 2006 to 2011. As there is no data available before 2008 on the number of Japanese encephalitis (JE...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2018.1564435

    authors: Muniaraj M,Rajamannar V

    更新日期:2019-01-01 00:00:00

  • Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials.

    abstract::Dengue is prevalent in the Asia-Pacific region. Participants of two immunogenicity and safety phase II studies conducted in Singapore and Vietnam (NCT0088089 and NCT00875524, respectively) were followed for up to four years after third vaccine dose of a recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TD...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/21645515.2019.1578595

    authors: Tran NH,Chansinghakul D,Chong CY,Low CY,Shek LP,Luong CQ,Fargo C,Wartel TA,Sun S,Skipetrova A,Bouckenooghe A

    更新日期:2019-01-01 00:00:00

  • Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety.

    abstract::Post licensure surveillance of adverse events following immunization (AEFI) is a fundamental activity to improve safety and maintain public confidence in vaccines.   Since 2011, the Liguria Region has been involved in the inter-regional project of post-marketing surveillance of AEFI, coordinated by the Italian Medicin...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.34360

    authors: Alicino C,Merlano C,Zappettini S,Schiaffino S,Della Luna G,Accardo C,Gasparini R,Durando P,Icardi G

    更新日期:2015-01-01 00:00:00

  • Awareness and acceptance of human papillomavirus (HPV) vaccination among males attending a major sexual health clinic in Wuxi, China: A cross-sectional study.

    abstract:OBJECTIVE:To study the awareness and acceptance of human papillomavirus (HPV) vaccination among sexually active men having sex with men (MSM) and men not having sex with men (MNSM) attending the largest sexual health clinic in Wuxi, China. METHODS:A questionnaire about participants' socio-demographic characteristics a...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2015.1099771

    authors: Zou H,Meng X,Jia T,Zhu C,Chen X,Li X,Xu J,Ma W,Zhang X

    更新日期:2016-06-02 00:00:00

  • Evaluation of the HPV 18 antibody response in Gardasil® vaccinees after 48 mo using a pseudovirion neutralization assay.

    abstract::The pseudo-neutralization assay (PsV) described in the current report allows for the creation of HPV18 pseudovirions in order to evaluate whether the antibody responses elicited following vaccination with Gardasil(®) are sufficient to neutralize the activity of these pseudovirions in vitro. The PsV assay evaluates a b...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.19179

    authors: Roberts C,Swoyer R,Bryan J

    更新日期:2012-04-01 00:00:00

  • Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults.

    abstract::The multicomponent meningococcal serogroup B vaccine, 4CMenB, has demonstrated effectiveness in preventing invasive MenB disease in infants and in controlling MenB outbreaks. The need for/timing of additional booster doses is not yet established. We reviewed eight studies that evaluated antibody persistence and booste...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2019.1627159

    authors: Martinón-Torres F,Nolan T,Toneatto D,Banzhoff A

    更新日期:2019-01-01 00:00:00

  • Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan.

    abstract:BACKGROUND:The study was aimed at comparative evaluation of seasonal influenza vaccine RIBSP versus commercial vaccine VAXIGRIP® for immunogenicity and safety in the course of clinical trial phase II on healthy subjects up to 60 years. METHODS:The trial involved 150 subjects in randomized 2:1 groups that received eith...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1705691

    authors: Sarsenbayeva G,Issagulov T,Kassenov M,Abitay R,Orynbayev M,Stukova M,Pisareva M,Davlyatshin T,Lespek K,Khairullin B

    更新日期:2020-08-02 00:00:00

  • Varicella vaccine strain infection in a non-immunocompromised patient. A case report and review of literature.

    abstract::Varicella live attenuated vaccine led to a significant reduction in morbidity and mortality from varicella zoster disease. Vaccine adverse effects are mostly mild. Immunosuppression is the main risk factor for severe varicella. Risk factors for disease following vaccination are less studied. We report a 12-month-old i...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1802976

    authors: Swed-Tobia R,Kassis I,Hanna S,Szwarcwort-Cohen M,Dovrat S,Dabaja-Younis H

    更新日期:2020-09-18 00:00:00

  • Efficacy of Mycobacterium vaccae immunotherapy for patients with tuberculosis: A systematic review and meta-analysis.

    abstract::Tuberculosis (TB) is a significant cause of illness and death worldwide. Immunotherapy has been investigated in the treatment of TB. The purpose of this study was to perform a meta-analysis investigating the effectiveness of the M. vaccae vaccine. Medline, Cochrane, EMBASE, and Google Scholar were searched until Novem...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/21645515.2017.1335374

    authors: Huang CY,Hsieh WY

    更新日期:2017-09-02 00:00:00